| Status: Recommended | |||
Paliperidone palmitate (Xeplion®) prolonged release suspension for injection is recommended as an option for use within NHS Wales for the maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone; and in selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, without prior stabilisation with oral treatment when psychotic symptoms are mild to moderate and a long acting injectable treatment is needed. |
|||
|
|||
Medicine details |
|||
| Medicine name | paliperidone palmitate (Xeplion®) | ||
| Formulation | 50 mg prolonged-release suspension for injection, 75 mg prolonged-release suspension for injection, 100 mg prolonged-release suspension for injection, 150 mg prolonged-release suspension for injection | ||
| Reference number | 1579 | ||
| Indication | Maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, it may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Resubmission | ||
| Status | Recommended | ||
| Advice number | 2512 | ||
| NMG meeting date | 05/09/2012 | ||
| AWMSG meeting date | 17/10/2012 | ||
| Ratification by Welsh Government | 09/11/2012 | ||
| Date of issue | 13/11/2012 | ||
| Date of last review | 30/08/2016 | ||